It was announced that Sunzen Biotech will be exiting from its animal health business to focus on human health products and loan financing services. Executive chairman, Ching Chee Pun shares with us the rationale behind this decision, the outlook and why they appear to have a weak track record when it comes to M&A.

Pharmaniaga Post-PN17 Betting Big on Biopharma
23:56

Khairy Jamaluddin: Back in the Running
34:25

Caught in the Chip War: Perspectives from the Netherlands
25:36